Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares increased 5.55% in pre-market trading to $585.02 after the company reported second quarter earnings. The company posted quarterly revenue of $998.6 million, crushing estimates of $887.8 million. Non-GAAP EPS for the second quarter was $2.89, also ahead of the analyst estimate of $2.77. Sales of Eylea (aflibercept) increased 50% year-over-year to $993 million, with roughly two-thirds of sales coming from the U.S.  Regeneron raised full-year 2015 Eylea sales to a 45% to 50% increase from 2014, up from the previous range of 30% to 35%. Aside from approved drugs, the company currently has 15 products in its pipeline. According to the 13 analysts polled by TipRanks in the last 3 months, 9 are bullish on the stock and 4 are neutral. The average 12-month price target on the stock is $545.58, marking a -1.5% potential downside from where the stock last closed.

Exelixis, Inc. (NASDAQ:EXEL) shares are up 4.58% in pre-market trading to $6.40 after Jim Cramer touted the stock on CNBC yesterday. Cramer said, “I’ve been recommending EXEL… Double down I think it’s terrific. That last drug approval was dynamite.” The company recently released positive Phase III rest results for Cabozantinib, the company’s pipeline kidney cancer therapy. The trial met its primary endpoint, though data was cut off before the second endpoint could be achieved. According to the 2 analysts polled by TipRanks in the last 3 months, 1 analyst is bullish on the stock and 1 is neutral. The average 12-month price target on the stock is $6.00, marking a -2% potential downside from where the stock last closed.

On Deck Capital Inc (NYSE:ONDK) shares dropped 10.31% in pre-market trading to $12.00 after Deutsche Bank downgraded the stock from Buy to Hold and lowered the price target from $18 to $14. The downgrade comes after the business loan company released second quarter earnings. Even though the earnings report topped estimates with reported EPS of $0.10 and quarterly revenue of $63.3 million, compared to estimates of $0.01 and $61.4 million, respectively, the downgrade took a hit on the stock. Deutsche Bank noted that although the company is well-positioned for long term success in online lending, there is currently significant risk. The analyst explained, “Given more balanced risk/reward and no clear path to a more sanguine competitive environment, we downgrade shares to Hold from Buy.” Based on the 8 analysts polled by TipRanks in the last 3 months, 5 are bullish on the stock, 2 are neutral, and 1 is bearish. The average 12-month price target on the stock is $19.43, marking a 45% potential upside from where the stock last closed.

Linn Energy LLC (NASDAQ:LINE) shares spiked 5.18% in pre-market trading to $3.28 after the oil and natural gas company announced monthly cash distribution and a monthly cash dividend. The monthly cash distribution is $0.1042 per unit, or $1.25 per unit on an annualized basis to be payable on August 18, 2015. The monthly cash dividend will be $0.1042 per common share, or $1.25 per share on an annualized basis payable August 19, 2015. Shares of Linn Energy have been falling since September 2014 and last closed at $3.28, hovering above its 52-week low of $3.26. According to the 5 analysts polled by TipRanks in the last 3 months, 2 are bullish on the stock and 3 are bearish. The 12-month average price target is $6.67, marking over a 100% potential upside from where the stock last closed.